ReviewActa pharmaceutica Sinica. B2023
Advancing drug delivery to articular cartilage: From single to multiple strategies.
Review in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Chitosan Nanoparticles as an Alternative Therapeutic Approach for Knee Osteoarthritis Treatment: A Systematic Review.International journal of nanomedicine · 2025Pooled it
- Research advances in microneedle-exosome delivery systems for the treatment of multisystem diseases.Regenerative therapy · 2026Review
- Advances in ultrasound-mediated nanozyme systems in therapeutic applications.Ultrasonics sonochemistry · 2026Review
- Hybrid exosomal nanomotors convert pathological ROS into transport-driving cues to enhance cartilage accumulation in osteoarthritis.Nature communications · 2026Article
- Engineering Poly(Lactic-co-Glycolic Acid) (PLGA)-Based Microspheres for Controlled Corticosteroid Delivery in Intra-Articular Cartilage.Pharmaceutics · 2026Article
- Cyclodextrin-Epichlorohydrin-Cyanoguanidine Polymer for Resveratrol Delivery to Enhance Human Chondrocyte Function in Cartilage Repair.Biomacromolecules · 2026Article
- Aptamer-Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap.Small science · 2026Article
- Nanocomposite hydrogels: benefits and attributes for osteoarthritis therapy.Journal of translational medicine · 2026Review
- Methyl gallate and hyaluronic acid-nanoconjugate targeting HSP90β for osteoarthritis therapy.Journal of nanobiotechnology · 2026Article
- Targeted immunomodulation for chronic diseases through advanced delivery platforms.Expert opinion on drug delivery · 2026Review
- Dual metabolic-inflammation modulation in MicroRNA@neutrophil-derived microvesicles achieve robust osteoarthritis therapy.Acta pharmaceutica Sinica. B · 2026Article
- Current progress of plant-derived exosome-like nanovesicles on the regulation of osteoporosis and osteoarthritis.Annals of medicine · 2025Review
- Carrier rocket-inspired hydrogel microspheres targeting subchondral bone osteoclast activity alleviate osteoarthritic pain and cartilage degeneration.Journal of nanobiotechnology · 2025Article
- Mechanobiochemical finite element model to analyze impact-loading-induced cell damage, subsequent proteoglycan loss, and anti-oxidative treatment effects in articular cartilage.Biomechanics and modeling in mechanobiology · 2025Article
- Genetically engineered chondrocyte-mimetic nanoplatform attenuates osteoarthritis by blocking IL-1β and restoring sirtuin-3.Science advances · 2025Article
- Influence of Scaffold Structure and Biomimetic Properties on Adipose Stem Cell Homing in Personalized Reconstructive Medicine.Biomimetics (Basel, Switzerland) · 2025Review
- Early Cost-Effectiveness Analysis of Intra-articular Delivery of a PBAE-DEX Conjugate for Osteoarthritis in a UK Population.Clinical drug investigation · 2025Article
- Unlocking the potential of injectable hydrogels for cartilage repair.Regenerative medicine · 2025Review
- ROS-Activated Nanohydrogel Scaffolds with Multi-Factors Controlled Release for Targeted Dual-Lineage Repair of Osteochondral Defects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- SPI1 activates mitochondrial unfolded response signaling to inhibit chondrocyte senescence and relieves osteoarthritis.Bone research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Articular cartilage (AC) injuries often lead to cartilage degeneration and may ultimately result in osteoarthritis (OA) due to the limited self-repair ability. To date, numerous intra-articular delivery systems carrying various therapeutic agents have been developed to improve therapeutic localization and retention, optimize controlled drug release profiles and target different pathological processes. Due to the complex and multifactorial characteristics of cartilage injury pathology and heterogeneity of the cartilage structure deposited within a dense matrix, delivery systems loaded with a single therapeutic agent are hindered from reaching multiple targets in a spatiotemporal matched manner and thus fail to mimic the natural processes of biosynthesis, compromising the goal of full cartilage regeneration. Emerging evidence highlights the importance of sequential delivery strategies targeting multiple pathological processes. In this review, we first summarize the current status and progress achieved in single-drug delivery strategies for the treatment of AC diseases. Subsequently, we focus mainly on advances in multiple drug delivery applications, including sequential release formulations targeting various pathological processes, synergistic targeting of the same pathological process, the spatial distribution in multiple tissues, and heterogeneous regeneration. We hope that this review will inspire the rational design of intra-articular drug delivery systems (DDSs) in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.